Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Buformin hydrochloride (NSC-528218) 是一种有效的 AMPK 激活剂,是一种双胍类的口服抗糖尿病药物。Buformin 延缓胃肠道对葡萄糖的吸收,增加胰岛素敏感性和葡萄糖对细胞的吸收,并抑制肝脏对葡萄糖的合成。Buformin 也具有抗癌活性,可用于各种癌症研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 283 | 现货 | ||
25 mg | ¥ 455 | 现货 | ||
50 mg | ¥ 663 | 现货 | ||
100 mg | ¥ 996 | 现货 | ||
200 mg | ¥ 1,530 | 现货 | ||
500 mg | ¥ 2,970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 195 | 现货 |
产品描述 | Buformin hydrochloride (NSC-528218) is a potent AMPK activator,an oral antidiabetic drug of the biguanide class. Buformin delays the absorption of glucose from the gastrointestinal tract increases insulin sensitivity and glucose uptake into cells and inhibits synthesis of glucose by the liver. Biguanides may antagonize the action of glucagon, thus reducing fasting glucose levels. |
体外活性 |
Buformin hydrochloride (0-10 mM; 5 days) inhibits SKBR3 and BT474 cells growth as a concentration-dependent manner, exhibits IC50 values of 246.7 μM and ?98.6 μM for erbB-2-overexpressing SKBR3 and BT474 cells, respectively[1]. Buformin hydrochloride (0-3 mM; 48 hours) increases the percentage of cells in G0/G1 phase and reduced the percentage of cells in S phase, especially in the SKBR3 cells[1]. Buformin hydrochloride (0-3 mM; 24 hours) suppresses RTK activation, including erbB-2 and IGF1R signaling downstream, and Akt activation/phosphorylation is inhibited in both SKBR3 and BT474 cells[1]. |
体内活性 | Buformin hydrochloride (oral administation; 7.6?mmol/kg of chow; 7 days) exhibits significantly reduced tumor volumes and weights, and?hinders mammary morphogenesis and proliferation in MMTV-erbB-2 transgenic mice[1]. |
别名 | NSC528218, NSC-528218, 盐酸丁双胍, NSC 528218 |
分子量 | 193.68 |
分子式 | C6H16ClN5 |
CAS No. | 1190-53-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/ml (309.79 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 5.1632 mL | 25.8158 mL | 51.6316 mL | 129.0789 mL |
5 mM | 1.0326 mL | 5.1632 mL | 10.3263 mL | 25.8158 mL | |
10 mM | 0.5163 mL | 2.5816 mL | 5.1632 mL | 12.9079 mL | |
20 mM | 0.2582 mL | 1.2908 mL | 2.5816 mL | 6.4539 mL | |
50 mM | 0.1033 mL | 0.5163 mL | 1.0326 mL | 2.5816 mL | |
100 mM | 0.0516 mL | 0.2582 mL | 0.5163 mL | 1.2908 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Buformin hydrochloride 1190-53-0 Chromatin/Epigenetic PI3K/Akt/mTOR signaling AMPK agent Type II diabete inhibit Inhibitor SKBR3 cervical cancer breast cancer biguanide analog BT474 NSC528218 NSC-528218 1-Butylbiguanide antidiabetic AMP-activated protein kinase 盐酸丁双胍 Buformin Buformin Hydrochloride NSC 528218 inhibitor